Unicycive Therapeutics/$UNCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Unicycive Therapeutics
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Ticker
$UNCY
Sector
Primary listing
Employees
23
Headquarters
Website
UNCY Metrics
BasicAdvanced
$74M
-
-$2.90
1.87
-
Price and volume
Market cap
$74M
Beta
1.87
52-week high
$8.25
52-week low
$3.86
Average daily volume
488K
Financial strength
Current ratio
2.176
Quick ratio
1.646
Total debt to equity
2.49
Interest coverage (TTM)
-634.96%
Profitability
EBITDA (TTM)
-30.451
Management effectiveness
Return on assets (TTM)
-51.00%
Return on equity (TTM)
-131.87%
Valuation
Price to book
3.61
Price to tangible book (TTM)
3.61
Price to free cash flow (TTM)
-1.376
Free cash flow yield (TTM)
-72.66%
Free cash flow per share (TTM)
-3.052
Growth
Earnings per share change (TTM)
-58.35%
3-year earnings per share growth (CAGR)
-34.24%
UNCY News
AllArticlesVideos
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Business Wire·7 days ago
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Business Wire·7 days ago
UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Unicycive Therapeutics stock?
Unicycive Therapeutics (UNCY) has a market cap of $74M as of August 25, 2025.
What is the P/E ratio for Unicycive Therapeutics stock?
The price to earnings (P/E) ratio for Unicycive Therapeutics (UNCY) stock is 0 as of August 25, 2025.
Does Unicycive Therapeutics stock pay dividends?
No, Unicycive Therapeutics (UNCY) stock does not pay dividends to its shareholders as of August 25, 2025.
When is the next Unicycive Therapeutics dividend payment date?
Unicycive Therapeutics (UNCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Unicycive Therapeutics?
Unicycive Therapeutics (UNCY) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.